美國Fate Therapeutics www.fatetherapeutics.com
位于圣地亞哥的Fate Therapeutics公司成立于2007年下半年，現(xiàn)在已經(jīng)引進了Jaenisch和Scripps研究所的Sheng Ding成為其科學領(lǐng)軍人物。2009年四月，該公司宣布了與Stemgent公司的合伙事宜，后者是一家干細胞試劑公司，在波士頓和圣地亞哥兩地設(shè)立了兩個總部，專門向生物技術(shù)公司和制藥公司提供誘導(dǎo)多能干細胞技術(shù)和誘導(dǎo)多能干細胞衍生的成熟細胞，用于毒理學檢測和初步的藥物篩選。公司的總裁兼CEO Paul Grayson說，目前，F(xiàn)ate公司處于一種“具有可持續(xù)性但不具有盈利性”的狀態(tài)，但是在三至七年中，他希望能將公司的第一個治療藥靶推向市場，它很可能與血液系統(tǒng)疾病有關(guān)。

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.
While embryonic stem cells opened the possibility for regenerative medicine, Fate Therapeutics is focusing on adult stem cells and induced pluripotent stem (iPS) cells.
Adult stem cells naturally exist in tissues or organs and are responsible for maintaining and repairing the tissue in which they are found. 
iPS cells are stem cells created from fully mature differentiated cells, like a skin cell, and promise to be of great use for drug discovery and development and personalized cell replacement therapies. 
Fate is using conventional drug discovery and iPS cell technology to identify small molecules and biologics to develop therapeutics for diseases and conditions that currently have limited to no treatment options.